Markets:

Overview

News

Currencies

International

Treasuries

Ascendis Pharma A/S - American Depositary Shares (NQ:ASND)

221.34 -6.07 (-2.67%)

Streaming Delayed Price Updated: 12:52 PM EDT, Mar 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ascendis Pharma A/S - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >

Here's How Much $1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today ↗

July 03, 2024

Via Benzinga

Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 15 Years ↗

June 26, 2024

Via Benzinga

If You Invested $100 In This Stock 15 Years Ago, You Would Have $4,100 Today ↗

May 31, 2024

Via Benzinga

(ASND) - Analyzing Ascendis Pharma's Short Interest ↗

May 28, 2024

Via Benzinga

$100 Invested In This Stock 10 Years Ago Would Be Worth $6,500 Today ↗

May 17, 2024

Via Benzinga

FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months ↗

May 15, 2024

Ascendis Pharma announces FDA's extension of the review date for TransCon PTH for adults with hypoparathyroidism to August 14, 2024. TransCon PTH aims to address low calcium levels due to...

Via Benzinga

Masters In Trading - Saturday, May 11 ↗

May 11, 2024

In this recap of the most recent trading session, I discuss earnings results and the market rally seen throughout the past week.

Via Talk Markets

$100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth This Much Today ↗

May 06, 2024

Via Benzinga

ASND Stock Earnings: Ascendis Pharma Reported Results for Q1 2024 ↗

May 02, 2024

Ascendis Pharma just reported results for the first quarter of 2024.

Via InvestorPlace

Looking Into Ascendis Pharma's Recent Short Interest ↗

April 26, 2024

Via Benzinga

$1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth This Much Today ↗

April 18, 2024

Via Benzinga

Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion ↗

April 06, 2024

ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates...

Via Talk Markets

Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years ↗

April 03, 2024

Via Benzinga

Here's How Much $100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today ↗

March 14, 2024

Via Benzinga

5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024 ↗

March 09, 2024

Things have been looking better for the biotech industry in 2024 after a decent performance in 2023. Here is a look at some biotech stocks that may provide stability to one's portfolio throughout the...

Via Talk Markets

$1000 Invested In This Stock 15 Years Ago Would Be Worth $45,000 Today ↗

February 23, 2024

Via Benzinga

How Is The Market Feeling About Ascendis Pharma? ↗

February 13, 2024

Via Benzinga

If You Invested $1000 In This Stock 10 Years Ago, You Would Have $70,000 Today ↗

February 08, 2024

Via Benzinga

These Five Small-Cap Stocks Under The Radar Are Expected To Surge, Says Stock Researcher ↗

March 03, 2024

Ethan Meyers, the research director at Westfield Capital Management, has a knack for identifying promising investments that have proven fruitful, especially for the Harbor Small Cap Growth Fund, where...

Via Benzinga

Earnings Scheduled For February 7, 2024 ↗

February 07, 2024

Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quarterly loss at $0.80 per share on revenue of $301.83 million.

Via Benzinga

Ascendis Pharma's Earnings: A Preview ↗

February 06, 2024

Via Benzinga

$100 Invested In Ascendis Pharma 5 Years Ago Would Be Worth This Much Today ↗

February 02, 2024

Via Benzinga

Ascendis Pharma's Growth Hormone Deficiency Candidate Outperforms in Phase 3 Trial ↗

December 19, 2023

Ascendis Pharma A/S (NASDAQ: ASND) released topline results from Phase 3 foresiGHt trial to compare the efficacy and safety of TransCon hGH (lonapegsomatropin) with placebo and daily hGH (human growth...

Via Benzinga

Analyst Expectations for Ascendis Pharma's Future ↗

November 09, 2023

Via Benzinga

Recap: Ascendis Pharma Q3 Earnings ↗

November 07, 2023

Via Benzinga

Preview: Ascendis Pharma's Earnings ↗

November 06, 2023

Via Benzinga

The Latest Analyst Ratings for Ascendis Pharma ↗

October 09, 2023

Via Benzinga

The Latest Analyst Ratings for Ascendis Pharma ↗

September 07, 2023

Via Benzinga

Impact on BioMarin's Sentiment: Voxzogo's Triumph Clouded by Uncertainty ↗

September 28, 2023

Raymond James initiated coverage on BioMarin Pharmaceuticals Inc (NASDAQ: BMRN) with a Market Perform rating, noting sparsity in

Via Benzinga

Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement

September 05, 2023

From Royalty Pharma plc

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.